The observed anti-cancer efficacy of AC-NKs with T-DM1 or SZ in each targeted cancer cell was attributed to its specific binding to T-DM1 or SZ on HER2-positive cancer cells or Trop-2 positive cancer cells, respectively. This evidence concerns the gene ERBB2 and cancer.